2006
DOI: 10.1111/j.1423-0410.2006.00856.x
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies to a novel antigen in acute hepatitis C virus infections

Abstract: A novel EIA with conformational and linear epitopes detected HCV antibodies in 17% of viraemic specimens missed by the standard reference EIA-3.0. Our research EIA appears to detect HCV antibodies closer to the initiation of acute hepatitis. Given that the average RNA-positive, antibody-negative window period is 56.4 days, this 17% yield would translate into a 10-day earlier detection of antibodies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0
2

Year Published

2007
2007
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 35 publications
(52 reference statements)
0
4
0
2
Order By: Relevance
“…The serological test used throughout was the HCV 3.0 enzyme-immunoassay (EIA) (Ortho Clinical Diagnostics, Raritan, New Jersey) which includes recombinant proteins representing linear epitopes from the Core, NS3, NS4 and NS5 regions (Chien et al, 1999;Lin et al, 2005) and is used to screen approximately 80% of the blood supply in the United States (US) for antibodies to HCV. Three unlicensed EIAs containing antigenic proteins not present in HCV 3.0 EIA 1) MEFA 7.1-NS3/4a, 2) F and Core, and 3) E1/E2 proteins were also used for a subset of samples (Tobler et al, 2007). MEFA 7.1 contains the linear epitopes used in licensed EIAs, including the latest EIA-3.0, in combination with genotype 1-3 specific epitopes.…”
Section: Serological Assaysmentioning
confidence: 99%
See 1 more Smart Citation
“…The serological test used throughout was the HCV 3.0 enzyme-immunoassay (EIA) (Ortho Clinical Diagnostics, Raritan, New Jersey) which includes recombinant proteins representing linear epitopes from the Core, NS3, NS4 and NS5 regions (Chien et al, 1999;Lin et al, 2005) and is used to screen approximately 80% of the blood supply in the United States (US) for antibodies to HCV. Three unlicensed EIAs containing antigenic proteins not present in HCV 3.0 EIA 1) MEFA 7.1-NS3/4a, 2) F and Core, and 3) E1/E2 proteins were also used for a subset of samples (Tobler et al, 2007). MEFA 7.1 contains the linear epitopes used in licensed EIAs, including the latest EIA-3.0, in combination with genotype 1-3 specific epitopes.…”
Section: Serological Assaysmentioning
confidence: 99%
“…Subjects TN9, TN78 and TN168 have previously been reported as sero-silent infections using HCV EIA 3.0 with normal plasma alanine aminotransferase (ALT) (Peoples et al, 2000;Stramer et al, 2004). Samples from subject TN9 and TN78 were also tested by three unlicensed EIA and were also seronegative (Tobler et al, 2007).…”
Section: Subjectsmentioning
confidence: 99%
“…Importantly, recent work from our laboratory verified the expression of the two coreϩ1/ARFP isoforms in the context of replicons derived from the genotype 2a HCV isolate JFH1 and revealed differences in the expression kinetics of the coreϩ1/ARFP isoforms during infection (17). Importantly, the detection of coreϩ1/ARFP-specific antibodies (18)(19)(20)(21)(22)(23)(24)(25) and T-cell responses in HCV-infected patients (26)(27)(28)(29) reported by several laboratories worldwide suggest that this protein is also expressed in vivo. However, coreϩ1/ARFP is not required for JFH1 HCV (genotype 2a) replication in cultured cells (30) and for HCV genotype 1a replication in vivo in chimpanzees (31).…”
mentioning
confidence: 57%
“…Concerning the biological relevance of core+1 protein, specific antibodies [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ] and T-cell responses [ 32 , 33 , 34 ] have been detected in HCV-infected individuals. Moreover, studies conducted by us revealed a high prevalence of core+1 antibodies in HCV patients with advanced cirrhosis [ 35 ] and hepatocellular carcinoma (HCC) [ 36 ], suggesting that core+1 antibodies in HCV infection may present a marker for the progression of liver disease and the development of liver cancer.…”
Section: Introductionmentioning
confidence: 99%